참고문헌
- Arriagada R, Bergman B, Dunant A, et al (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 350, 351-60. https://doi.org/10.1056/NEJMoa031644
- Bahl A, Falk S (2001). Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Br J Cancer, 84, 1143-5. https://doi.org/10.1054/bjoc.2000.1740
- Friboulet L, Olaussen KA, Pignon JP, et al (2013). ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med, 368, 1101-10. https://doi.org/10.1056/NEJMoa1214271
- Friedberg EC (2001). How nucleotide excision repair protects against cancer. Nature reviews. Cancer, 1, 22-33.
- Hays JB, Hoffman PD, Wang H (2005). Discrimination and versatility in mismatch repair. DNA repair, 4, 1463-74. https://doi.org/10.1016/j.dnarep.2005.09.002
- Jassem J, Skokowski J, Dziadziuszko R, et al (2000). Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg, 119, 1141-6. https://doi.org/10.1067/mtc.2000.105825
- Jemal A, Murray T, Ward E, et al (2005). Cancer statistics, 2005. CA Cancer J Clin, 55, 10-30. https://doi.org/10.3322/canjclin.55.1.10
- Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30. https://doi.org/10.3322/canjclin.56.2.106
- Kamal NS, Soria JC, Mendiboure J, et al (2010). MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res, 16, 1206-15. https://doi.org/10.1158/1078-0432.CCR-09-2204
- Kummar S, Chen A, Parchment RE, et al (2012). Advances in using PARP inhibitors to treat cancer. BMC medicine, 10, 25. https://doi.org/10.1186/1741-7015-10-25
- Li X-D, Han J-C, Zhang Y-J, et al (2013). Common variations of DNA repair genes are associated with response to platinumbased chemotherapy in NSCLCs. Asian Pac J Cancer Prev, 14, 145-8. https://doi.org/10.7314/APJCP.2013.14.1.145
- Michels J, Vitale I, Galluzzi L, et al (2013). Cisplatin resistance associated with PARP hyperactivation. Cancer Res, 73, 2271-80. https://doi.org/10.1158/0008-5472.CAN-12-3000
- Olaussen K A, Adam J, Vanhecke E, et al (2013). PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer, 80, 216-22. https://doi.org/10.1016/j.lungcan.2013.01.014
- Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91. https://doi.org/10.1056/NEJMoa060570
- Ozdemir O, Ozdemir P, Veral A, et al (2013). ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev, 14, 4679-83. https://doi.org/10.7314/APJCP.2013.14.8.4679
- Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Parsons JL, Dianova, II, Allinson SL, Dianov GL (2005). Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts. FEBS J, 272, 2012-21. https://doi.org/10.1111/j.1742-4658.2005.04628.x
- Pierceall WE, Olaussen KA, Rousseau V, et al (2012). Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol, 23, 2245-52. https://doi.org/10.1093/annonc/mdr624
- Pignon JP, Tribodet H, Scagliotti GV, et al (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9. https://doi.org/10.1200/JCO.2007.13.9030
- Rosell R, Lord RV, Taron M, Reguart N (2002). DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung cancer, 38, 217-27. https://doi.org/10.1016/S0169-5002(02)00224-6
- Rosell R, Skrzypski M, Jassem E, et al (2007). BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PloS one, 2, e1129. https://doi.org/10.1371/journal.pone.0001129
- Roth JA, Carlson JJ (2011). Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer, 12, 393-401. https://doi.org/10.1016/j.cllc.2011.04.005
- Rouleau M, Patel A, Hendzel MJ, et al (2010). PARP inhibition: PARP1 and beyond. Nat Rev Cancer, 10, 293-301. https://doi.org/10.1038/nrc2812
- Scartozzi M, Franciosi V, Campanini N, et al (2006). Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 53, 103-9. https://doi.org/10.1016/j.lungcan.2006.03.008
- Vageli DP, Zaravinos A, Daniil Z, et al (2012). hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment. Int J Biol Markers, 27, e400-4. https://doi.org/10.5301/JBM.2012.9420
- Wang D, Xiang DB, Yang XQ, et al (2009). APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer, 66, 298-304. https://doi.org/10.1016/j.lungcan.2009.02.019
- Zhang Z-Y, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. https://doi.org/10.7314/APJCP.2012.13.6.2583
피인용 문헌
- Assessment of the Prognostic Value of Methylation Status and Expression Levels of FHIT, GSTP1 and p16 in Non-Small Cell Lung Cancer in Egyptian Patients vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4281
- Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3672-z
- Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3487-y
- Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy vol.11, pp.1, 2015, https://doi.org/10.3892/ol.2015.3913
- High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5169
- Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer vol.12, pp.9, 2016, https://doi.org/10.2217/fon.16.21
- DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer vol.9, pp.8, 2018, https://doi.org/10.1111/1759-7714.12785